Health Ever Bio-Tech

Focus: Health Ever Bio-Tech is a Taiwan-based botanical drug biotech focused on oncology and urological indications, leveraging multi-carotenoid compounds (MCS) as its core platform technology.

Oncology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Health Ever Bio-Tech

AI assessmentNot Hiring

No open roles listed right now. Follow Health Ever Bio-Tech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention

Prostate Cancer

N/A

MCS-2 soft-gel capsule

Healthy

Phase 1

Help build intelligence for Health Ever Bio-Tech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead development of Phase 3 programs in benign prostatic hyperplasia and lower urinary tract symptoms with near-term regulatory catalysts
Participate in pioneering botanical drug formulations, a differentiated approach in oncology and urology markets
Join a focused biotech with lean portfolio (9 active trials) where individual contributions have visible impact on program outcomes

Watch Out For

No active hiring reported (0 open roles) signals limited near-term growth or potential organizational stasis
Minimal public data on financials, funding, employee count, and leadership raises questions about transparency and stability
Small pipeline concentration in prostate-related indications (7 of 9 trials) and lack of published data limit competitive visibility

Generated by Claude from Health Ever Bio-Tech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Placebo

Prostate Cancer

Phase 2

MCS-2 15 mg/day

Lower Urinary Tract Symptoms

Phase 2/3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo